RECRUITING

Tailored Electronic Intervention to Improve Therapy in a Diverse Cohort of Patients with Heart Failure

Conditions

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

Recent medical guidelines for the management of heart failure (HF) have established a combination of specific classes of medications as the best treatment for patients with heart failure with reduced ejection fraction (HFrEF). However, studies have shown that these medications, known together as guideline-directed medical therapy (GDMT), are not being used in clinical practice less often than they could be. Several tools to promote broader use of these treatments (including patient checklists) have shown promise for increasing use of GDMT. However, these tools have not been broadly implemented within large health systems. The goal of this study is to see if using these tools broadly within cardiology clinics will increase the use of GDMT. This study is important because it could help improve the use of GDMT, which may lead to improved patient care and outcomes.

Official Title

Tailored Electronic Intervention to Improve Therapy in a Diverse Cohort of Patients with Heart Failure

Quick Facts

Study Start:2025-02
Study Completion:2026-06
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06847438

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Ejection fraction (EF) less than or equal to 40% by echocardiogram performed in the prior 18 months
  2. * Diagnosis of heart failure
  1. * Heart failure (HF) etiology for which GDMT is not indicated: including hypertrophic or restrictive cardiomyopathy (e.g. amyloid cardiomyopathy), constrictive pericarditis, or complex congenital heart disease
  2. * End-stage HF requiring continuous inotrope infusion, heart transplant, or left ventricular assist device
  3. * Estimated glomerular filtration rate (eGFR) \< 15 mL/min/1.73m\^2
  4. * Any conditions other than HF that are likely to alter the patient's status over 6 months, indicated by active hospice status

Contacts and Locations

Study Contact

Neal W Dickert, MD, PhD
CONTACT
404-712-6834
njr@emory.edu

Principal Investigator

Neal W Dickert, MD, PhD
PRINCIPAL_INVESTIGATOR
Emory University

Study Locations (Sites)

Emory Saint Joseph's Hospital
Atlanta, Georgia, 30308
United States
Emory University Hospital Midtown
Atlanta, Georgia, 30308
United States
Emory University Hospital
Atlanta, Georgia, 30322
United States
Emory Johns Creek Hospital
Johns Creek, Georgia, 30097
United States

Collaborators and Investigators

Sponsor: Emory University

  • Neal W Dickert, MD, PhD, PRINCIPAL_INVESTIGATOR, Emory University

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2025-02
Study Completion Date2026-06

Study Record Updates

Study Start Date2025-02
Study Completion Date2026-06

Terms related to this study

Additional Relevant MeSH Terms

  • Heart Failure